УКР  |  ENG

Клинические исследования в Украине

Форум Пациентам

Исследования / № 00274456

Описание
Краткое названиеPhase II Trial Comparing ABI-007 to Taxotere in First Line Therapy of Patients With Stage IV Breast Cancer
Полное названиеA Randomized Phase II Study of Weekly or Every 3 Weeks ABI-007 Versus Every 3 Weeks Taxotere as First Line Therapy of Stage IV (Metastatic) Breast Cancer
СпонсорAbraxis BioScience, LLC.
Industry
ИсточникAbraxis BioScience, LLC.
Под контролемUnited States: Food and Drug Administration
Ukraine: Ministry of Health
No
Краткое описаниеThis is an open-label study conducted at study sites in Russia and the Ukraine comparing the
toxicity and antitumor activity of ABI-007 to Taxotere.
СостояниеАктивный, набор окончен
Дата началаNovember 2005
ФазаPhase 2
Подробное описаниеThis is an open-label, randomized study to compare the following regimens with respect to
toxicity and antitumor activity: the MTD of ABI 007 for a q3w schedule (300 mg/m2 every 3
weeks); ABI-007 100 mg/m2 administered weekly for 3 weeks with a 1 week rest; ABI-007 150
mg/m2 administered weekly for 3 weeks with a 1 week rest; and the standard dose and schedule
of Taxotere (100 mg/m2 every 3 weeks).
Вид исследованияAllocation: Randomized, Control: Active Control, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Набор0
КритерииInclusion Criteria:

- Pathologically confirmed adenocarcinoma of the breast.

- No prior chemotherapy for metastatic breast cancer.

- Stage IV disease

- Measurable disease

- At least 3 weeks since prior cytotoxic chemotherapy(patients should have recovered
from all acute effects of such therapy.

- At least 4 weeks since radiotherapy, with full recovery. The measurable disease must
be completely outside the radiation portal or there must be radiologic or clinical
exam proof of progressive disease within the radiation portal.

- At least 4 weeks since major surgery, with full recovery.

- ECOG performance status 0-2.

- Age ?‰?18 years.

- Patient has the following blood counts at Baseline:

- ANC ?‰?1.5 x 109 cells/L;

- Platelets ?‰?100 x 109 cells/L

- Hgb ?‰?9 g/dL.

- Patient has the following blood chemistry levels at Baseline:

- AST (SGOT), ALT (SGPT)?‰?2.5x upper limit of normal range (ULN);

- Total bilirubin normal;

- Alkaline phosphatase ?‰?2.5x ULN (unless bone metastasis is present in the absence of
liver metastasis);

- Creatinine ?‰?1.5 mg/dL.

- Peripheral neuropathy Grade 0 or 1.

- If female of childbearing potential, pregnancy test is negative (within 72 hours of
the first dose of study drug).

- If fertile, the patient agrees to use an effective method to avoid pregnancy for the
duration of the study.

- Informed consent has been obtained

Exclusion Criteria:

- Prior neo-adjuvant or adjuvant chemotherapy is allowed. No prior chemotherapy for
metastatic disease is allowed. If a taxane was part of the adjuvant regimen, at least
one year should have transpired since completion of taxane regimen.

- Cumulative life-time dose of doxorubicin >360 mg/m2. Doxorubicin is allowed as prior
neo-adjuvant or adjuvant therapy but not for metastatic disease.

- Concurrent immunotherapy or hormonal therapy for breast cancer.

- Parenchymal brain metastases, unless documented to be clinically and radiographically
stable for at least 6 months after treatment.

- Serious intercurrent medical or psychiatric illness, including serious active
infection.

- History of class II-IV congestive heart failure.

- History of other malignancy within the last 5 years which could affect the diagnosis
or assessment of breast cancer.

- Patients who have received an investigational drug within the previous 3 weeks.

- Patient is currently enrolled in a different clinical study in which investigational
procedures are performed or investigational therapies are administered. Also, a
patient may not enroll in such clinical trials while participating in this study.

- Pregnant or nursing women

- Patients with prior hypersensitivity to both Taxol and Taxotere.
ПолFemale
Минимальный возраст18 Years
Максимальный возрастN/A
УсловиеMetastatic Breast Cancer
Применяемое лечение
DrugAraxane versus Taxotere
Контакты и расположение
Kiev , 01021Study Sites in Russia and the Ukraine
2011 © Клинические испытания в Украине